<DOC>
	<DOCNO>NCT01767155</DOCNO>
	<brief_summary>Open-label , randomize , active-controlled , two-arm Phase III study compare efficacy safety AEZS-108 doxorubicin . The study include 500 patient endometrial cancer resistant platinum/taxane-based chemotherapy .</brief_summary>
	<brief_title>Zoptarelin Doxorubicin ( AEZS 108 ) Second Line Therapy Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Women â‰¥ 18 year age 2 . Histologically confirm endometrial cancer 3 . Advanced ( FIGO stage III IV ) , recurrent metastatic disease . 4 . Measurable nonmeasurable disease progress since last treatment . 5 . 5 . Patients advance , recurrent metastatic endometrial cancer receive one chemotherapeutic regimen platinum taxane ( either adjuvant first line treatment ) progress . 6 . Availability fresh archival FFPE tumor specimen analysis LHRH receptor expression . 1 . ECOG performance status &gt; 2 . 2 . Inadequate hematologic , hepatic renal function 3 . Red blood cell transfusion within 2 week prior anticipate start study treatment . 4 . History myocardial infarction , acute inflammatory heart disease , unstable angina , uncontrolled arrhythmia within past 6 month . 5 . Impaired cardiac function define leave ventricular ejection fraction ( LVEF ) &lt; 50 % ( study site 's low limit normal ) measure MUGA ECHO . 6 . Concomitant use prohibit therapy ( specify protocol ) 7 . Chemo , immune , hormonetherapy within 5 elimination half life time 4 week prior randomization , whichever short . Radiotherapy ( include pre postoperative brachytherapy ) within 4 week prior randomization . 8 . Previous anthracyclinebased chemotherapy ( daunorubicin , doxorubicin , epirubicin , idarubicin , mitoxantrone valrubicin ) , formulation . 9 . Anticipated ongoing concomitant anticancer therapy study . 10 . History serious comorbidity uncontrolled illness would preclude study therapy , active tuberculosis active infection . 11 . Brain metastasis , leptomeningeal disease . 12 . Pregnant lactate female female childbearing potential employ adequate contraception . 13 . Subjects know hypersensitivity peptide drug , include LHRH agonist . 14 . Receipt 2 prior cytotoxic chemotherapy regimen advance , recurrent , metastatic endometrial cancer . 15 . Prior treatment AEZS108 . 16 . Use LHRH agonist antagonist treatment within 6 month prior randomization . 17 . Malignancy within last 5 year except nonmelanoma skin cancer . 18 . Any concomitant disease condition would interfere subject ' proper completion protocol assignment . 19 . Concomitant recent treatment investigational drug ( within 4 week 5 elimination half life time prior anticipated start study treatment ) . 20 . Lack ability willingness give inform consent . 21 . Anticipated nonavailability study visits/procedures .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>